Deutsche Bank Ag\ Autolus Therapeutics PLC Transaction History

Deutsche Bank Ag\

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 04, 2021	SELL	$5.32 - $7.37 $79,140 - $109,636	-14,876 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$4.78 - $7.96 $71,107 - $118,412	14,876 New	14,876 $99,000
Q3 2019 Nov 14, 2019	SELL	$9.79 - $16.72 $119,643 - $204,335	-12,221 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$15.1 - $31.25 $183,147 - $379,031	12,129 Added 13183.7%	12,221 $196,000
Q1 2019 May 15, 2019	BUY	$24.38 - $34.71 $2,242 - $3,193	92 New	92 $2,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $208M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.